Orchid Pharma Ltd (NSE: ORCHPHARMA, BSE: 524372) is a Chennai, Tamil Nadu-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹4,622 Cr, it ranks #882 by market cap among the 6,137 Indian listed companies on FinBizNet, and #29 of 86 in Medicinal Chemicals and Botanical Products. At ₹823.30 (as of 25 Oct 2026), the share price is 28.0% below its 52-week high of ₹1,143.50 and 71.5% above its 52-week low of ₹480.00. The share price is up 13.0% over one year and down 16.7% over three months.
| Current Price | ₹823.30 |
|---|---|
| Market Cap | ₹4,622 Cr |
| NSE Symbol | ORCHPHARMA |
| BSE Code | 524372 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 538.6 |
| Return on Equity | 0.70% |
| Return on Assets | 0.12% |
| 52-Week Range | ₹480.00 – ₹1,143.50 |
| 1-Year Price Change | +13.0% |
| 3-Month Price Change | -16.7% |
| Beta (1Y) | 0.74 |
| Headquarters | Chennai, Tamil Nadu |
| Website | www.orchidpharma.com |
| Revenue | ₹304 Cr |
|---|---|
| Net Profit | ₹3 Cr |
| Net Margin | 0.8% |
| EPS (Basic) | ₹0.54 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. Its active pharmaceutical ingredients product portfolio includes oral cephalosporins, injectable cephalosporins; human and veterinary products; and antibiotics, including betalactam, macrolide, fluoroquinolone, and imidazole. The company also exports its products to approximately 40 countries internationally. The company was formerly known as Orchid Chemicals & Pharmaceuticals Limited and changed its name to Orchid Pharma Limited in October 2015. Orchid Pharma Limited was incorporated in 1992 and is headquartered in Chennai, India. Orchid Pharma Limited operates as a subsidiary of Dhanuka Laboratories Limited.
1. Pharmaceuticals-This segment engages in the research, manufacture, and marketing of active pharmaceutical ingredients and finished dosage forms. 2. Bulk-This segment manufactures active pharmaceuticals ingredients. 3. Formulation-This segment manufactures and sells finished dosage forms. 4. Corporate-0
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,21,995 Cr | 36.4 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,020 Cr | 22.2 | 18.32% | ₹8,017 Cr | +14.7% |
| Laurus Labs Ltd | ₹1,11,310 Cr | 125.3 | 17.74% | ₹2,026 Cr | +125.7% |
| Cipla Limited | ₹1,07,048 Cr | 27.6 | 11.74% | ₹7,119 Cr | -14.7% |
| Dr.Reddys Lab | ₹1,02,611 Cr | 24.1 | 11.52% | ₹8,698 Cr | -0.9% |
| Aurobindo Pharma Ltd. | ₹95,910 Cr | 26.8 | 9.93% | ₹9,150 Cr | +41.7% |
| Mankind Pharma | ₹93,977 Cr | 48.7 | 12.45% | ₹4,031 Cr | -9.9% |
| Lupin Ltd | ₹89,426 Cr | 16.6 | 26.91% | ₹8,277 Cr | -1.1% |
| Orchid Pharma Ltd | ₹4,622 Cr | 538.6 | 0.70% | ₹304 Cr | +13.0% |
Listed by market capitalisation. Ratios are shown for context only.
Orchid Pharma Ltd is trading at ₹823.30, with a market capitalisation of ₹4,622 Cr.
Orchid Pharma Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Orchid Pharma Ltd has a P/E of 538.6 and a return on equity of 0.70%.
Orchid Pharma Ltd is listed on the NSE under the symbol ORCHPHARMA and on the BSE under the scrip code 524372.
Orchid Pharma Ltd's share price is up 13.0% over one year and down 16.7% over three months. Its 52-week range is ₹480.00 to ₹1,143.50.
In Q1 FY27, Orchid Pharma Ltd reported revenue of ₹304 Cr and net profit of ₹3 Cr, with basic EPS of ₹0.54 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.